POMC and essential hypertension: In another study of 524 patients with essential hypertension, LCI699 administered at doses between 0.25 and 1 mg resulted in placebo-corrected reductions in ambulatory systolic and diastolic blood pressures of 6–9 mmHg and 3–6 mmHg, respectively after 8 weeks of treatment [39]; ACTH-stimulated cortisol release was suppressed in approximately 20% of subjects receiving LCI699 at a total daily dose of 1 mg in that study.